Cited by 843Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Open access

Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Links, Matthew, Gebski, Val, Mok, Tony, Yang, James Chih-Hsin·2017·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2016.10.007

Open this paper in CoChat — free account Open PDF

Abstract

Introduction We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC.Methods Randomized trials comparing immune checkpoint inhibitors against chemotherapy were identified. We retrieved the hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS) of the intention-to-treat population and EGFR mutation-defined subgroups. We used the fixed-effects inverse variance-weighted method to pool estimates of treatment efficacy. Statistical tests were two sided.Results In the three included studies that compared immune checkpoint inhibitors (nivolumab [n = 292], pembrolizumab [n = 691], and atezolizumab [n =144]) against docetaxel (n = 776), immune checkpoint inhibitors significantly prolonged OS over that with docetaxel overall (n = 1903, HR = 0.68, 95% CI: 0.61-0.77, p < 0.0001) and in the EGFR wild-type subgroup (n = 1362, HR = 0.66, 95% CI: 0.58-0.76, p < 0.0001) but not in the EGFR-mutant subgroup (n = 186, HR = 1.05, 95% CI: 0.70-1.55, p < 0.81; treatment-mutation interaction p = 0.03).Conclusion In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. Mechanisms of acquired resistance to first-line tyrosine kinase inhibitor therapy should be elucidated to guide selection of second-line treatment for these patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2016.10.007

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Self-citation
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,268
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710

Flagged first, then by citations

Show all 15 references

Sorted by citations

Items 501–600 of 843

Survival benefit of anlotinib in T790M ‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study
Chen, Y., Liu, H., Hu, N., Wang, Y., Yang, Z., Zhang, J., & Han, B. (2023) · Cancer Medicine · doi:10.1002/cam4.6232 · Cited by 9
KEYNOTE-024: Unlocking a pathway to lung cancer cure?
Rusch, V. W., Chaft, J. E., & Hellmann, M. D. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.10.155 · Cited by 9
Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
Velázquez, A. I., & McCoach, C. E. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.31 · Cited by 9
Clinical importance of VEGFC and PD‐L1 co‐expression in lung adenocarcinoma patients
Qin, T., Xia, J., Liu, S., Wang, J., Liu, H., Zhang, Y., Jia, Y., & Li, K. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13354 · Cited by 9
Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy
Lau, S. C. M., Poletes, C., Le, L. W., Mackay, K. M., Fares, A. F., Bradbury, P. A., Shepherd, F. A., Tsao, M., Leighl, N. B., Liu, G., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.006 · Cited by 9
Characterization of the Immune Cell Infiltration Landscape Uncovers Prognostic and Immunogenic Characteristics in Lung Adenocarcinoma
Wang, X., Xu, Z., Liu, Z., Lin, W., Cao, Z., Feng, X., Gao, Y., & He, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.902577 · Cited by 9
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
Friedman, J. S., Jun, T. W., Rashidipour, O., Huang, K., Ellis, E., Kadaba, P., Belani, P. B., Nael, K., Tsankova, N. M., Sebra, R., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03381-y · Cited by 9
Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancer
Taniguchi, Y., Takeda, M., Tamiya, A., Kasai, T., & Atagi, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy401 · Cited by 9
The efficacy of immune checkpoint inhibitors in advanced non‑small cell lung cancer harboring driver mutations
Sakamoto, H., Tanaka, H., Shiratori, T., Baba, K., Ishioka, Y., Itoga, M., Taima, K., Hasegawa, Y., Takanashi, S., & Tasaka, S. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1838 · Cited by 9
Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer
Muthusamy, B., & Pennell, N. A. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.012 · Cited by 9
Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis
Inoue, T., & Narukawa, M. (2022) · Cancer Control · doi:10.1177/10732748221140694 · Cited by 8
Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations
Jun, S., Park, S., Sun, J., Lee, S., Ahn, J. S., Ahn, M., Cho, J., & Jung, H. A. (2023) · Cancers · doi:10.3390/cancers15225450 · Cited by 8
Tumour- and Non-Tumour-Associated Factors That Modulate Response to PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer
Khalil, M., & Tsao, M. (2025) · Cancers · doi:10.3390/cancers17132199 · Cited by 9
Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns
Zhang, Y., Dai, X., Liang, J., Yang, C., Wan, C., Sun, L., Qiao, Q., Li, S., Bao, X., Chen, X., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108715 · Cited by 8
Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
Ma, K., Huang, F., Wang, Y., Kang, Y., Wang, Q., Tang, J., Sun, P., Lou, J., Qiao, R., Si, J., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4781 · Cited by 8
Neutrophil to lymphocyte ratio may predict efficacy of anti-PD-1 inhibitors in advanced EGFR-mutant non-small cell lung cancer: retrospective cohort study
Chen, J., Zheng, Q., Zhu, S., Qiu, D., & Wang, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-54557-0 · Cited by 8
Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study
Schwegler, C., Kaufmann, D., Pfeiffer, D., Aebi, S. P., Diebold, J., & Gautschi, O. P. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2268-y · Cited by 8
Immunotherapy in Non-Small-Cell Lung Cancer: A Bridge Between Research and Clinical Practice
Passiglia, F., Commendatore, O., Vitali, M., & Conca, R. (2018) · Future Oncology · doi:10.2217/fon-2018-0098 · Cited by 8
Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
Tozuka, T., Seike, M., Minegishi, Y., Kitagawa, S., Kato, T., Takano, N., Hisakane, K., Takahashi, S., KOBAYASHI, K. P., Kashiwada, T., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s168598 · Cited by 8
Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance
Moon, P. K., Tran, S., & Minhas, P. S. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1784-8 · Cited by 8
Neoadjuvant immunotherapy plus chemotherapy achieved pathologic complete response in stage IIIB lung adenocarcinoma harbored EGFR G779F: a case report
Wang, Y., Yang, X., Tian, X., Jia, Z., Bing, Z., Cao, L., Gao, C., Cao, Z., Li, S., & Liang, N. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1692 · Cited by 9
Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having EGFR Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer–American Society of Clinical Oncology CancerLinQ Study
Behera, M., Jiang, R., Huang, Z., Bunn, B., Wynes, M. W., Switchenko, J. M., Scagliotti, G. V., Belani, C. P., & Ramalingam, S. S. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100592 · Cited by 8
Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
Xu, J., Zhou, L., Lü, Y., Su, X., Cheng, P., Li, D., Gao, H., Li, H., Yuan, W., Zhang, L., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s230399 · Cited by 8
Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer
Li, Y., Chen, Z., Tao, W., Sun, N., & He, J. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02868-w · Cited by 8
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis
Pang, L., Zhuang, W., Chen, Z., Liao, J., Li, M.-D., Zhang, L., Fang, W., & Zhang, Y. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7092 · Cited by 7
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee
Jones, S. B., Chan, C., Filippi, A. R., Harada, K., Louie, A. V., Lindsay, C. R., Nadal, E., Schuffenegger, P. M., Woolf, D., & Finn, C. F. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.05.004 · Cited by 10
Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy
Shi, X., Deng, W., Pan, Y., Chen, Y., Wang, Y., & Wu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691980 · Cited by 9
Immunotherapy in EGFR-mutant non-small cell lung cancer
Wang, L., Xian, X., Ke, H., & Wang, K. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01927-1 · Cited by 7
Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
Zhai, X., Jing, X., Li, J., Tian, Y., Xu, S., Wang, M., & Zhu, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.556275 · Cited by 6
Thyroid cancer risk prediction model using m6A RNA methylation regulators: integrated bioinformatics analysis and histological validation
Zhou, W., Lin, J., Liu, J., Zhang, R., Fan, A., Xie, Q., Liu, H., & Fan, D. (2023) · Aging · doi:10.18632/aging.204525 · Cited by 7
The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study
Yin, X., Liu, X., Ren, F., & Meng, X. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03712-7 · Cited by 8
The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations
Decoster, L., Giron, P., Mignon, S., & Grève, J. D. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.08 · Cited by 7
Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
Passiglia, F., Raez, L. E., & Rolfo, C. D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.92 · Cited by 7
Hyperprogression after immunotherapy: A comprehensive review.
Çakır, M. O., Kırca, Ö., Gunduz, S. G., & Özdoğan, M. (2019) · PubMed · Cited by 7
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?
Lee, J., & Ahn, M. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000698 · Cited by 6
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
Park, J. H., You, G. L., Ahn, M., Kim, S.-W., Hong, M. H., Han, J., Ock, C.-Y., Lee, J.-S., Oh, I., Lee, S. Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03527-4 · Cited by 7
USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
Yang, D., Feng, Y., Lu, H., Chen, K., Xu, J., Li, P., Wang, T., Xia, D., & Wu, Y. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200292 · Cited by 8
EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer
Früh, M., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz185 · Cited by 7
Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors
Nakagawa, N., & Kawakami, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.952393 · Cited by 7
Tackling the Immunotherapy Conundrum: Advances and Challenges for Operable Non-Small-Cell Lung Cancer Treatment
Attieh, F., Chartouni, A., Boutros, M., Mouawad, A., & Kourié, H. R. (2023) · Immunotherapy · doi:10.2217/imt-2023-0128 · Cited by 7
Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations
Taniguchi, Y., Tamiya, A., Ishii, S., & Atagi, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy087 · Cited by 7
PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?
Heigener, D. F., & Reck, M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.013 · Cited by 7
Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?
Chalmers, A. W., Patel, S. B., & Akerley, W. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.160 · Cited by 8
Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?
Latif, H., & Liu, S. V. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.03.6 · Cited by 7
CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC
Pacheco, J. M., & Schenk, E. L. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1623 · Cited by 7
Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
Bianco, A., & Campbell, S. F. M. (2019) · Translational Cancer Research · doi:10.21037/tcr.2018.11.06 · Cited by 7
RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting
Wallen, Z. D., Tierno, M. B., Schnettler, E. K., Roos, A., Green, M. F., Amoah, K. A., Previs, R. A., Hastings, S. M., Pabla, S., Jensen, T. J., et al. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1550706 · Cited by 6
Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Chemotherapy-Naïve Advanced Non–Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized Trials
Huang, L., Zhang, S., Sun, L., Ma, J., & Han, C. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00907 · Cited by 7
Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers
Shang, X., Geng, X., Wang, Z., Yuan, S., Ding, S., Liu, G., Ma, X., Sun, X., Wang, H., Sun, Y. H., et al. (2025) · Advanced Science · doi:10.1002/advs.202513182 · Cited by 6
Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review
Bischoff, H., Gendarme, S., Somme, L., CHOUAID, C., & Schött, R. (2025) · Current Oncology · doi:10.3390/curroncol32110626 · Cited by 7
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
Zhou, D. D.-X., Lord, S. J., Lin, F. P. Y., Cooper, W. A., Zaheed, M., Simes, R. J., John, T., & Lee, C. K. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108891 · Cited by 6
Self-citation
Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
Deng, H., Lin, X., Xie, X., Yang, Y., Wang, L., Wu, J., Liu, M., Xie, Z., Qin, Y., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700023 · Cited by 6
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer
Shah, A. T., Blanchard, I., Padda, S. K., Wakelee, H. A., & Neal, J. W. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.06.006 · Cited by 6
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
Birsen, G., Gounant, V., Girard, N., Cadranel, J. L., Monnet, I., Donzel‐Raynaud, C., Fabre, E., Leprieur, E. G., Leroy, K., Damotte, D., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-263 · Cited by 7
Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
Liao, X., He, T., Wan, X., Liu, P., Li, J., He, Y., & Wang, Y. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.70025 · Cited by 6
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
Kanazu, M., Mori, M., Kimura, M., Nishino, K., Shiroyama, T., Nagatomo, I., Ihara, S., Komuta, K., Suzuki, H., Hirashima, T., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13718 · Cited by 6
Resistance to Immunotherapy: Mechanisms and Means for Overcoming
Salkeni, M. A., Shin, J. Y., & Gulley, J. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_2 · Cited by 6
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
Su, P., Chang, G., Hsiao, S.-H., Hsia, T., Lin, M., Lin, M., Shih, J., Yang, C., Yang, S.-H., & Chen, Y. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100292 · Cited by 6
PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors
Lasvergnas, J., Fallet, V., Duchemann, B., Jouveshomme, S., Cadranel, J. L., & CHOUAID, C. (2023) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2023.101018 · Cited by 6
Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
Patel, S. P., & Patel, J. D. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02680-1 · Cited by 6
Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review
McMahon, D. J., McLaughlin, R. A., & Naidoo, J. (2024) · Cancers · doi:10.3390/cancers16030527 · Cited by 7
“My Patient Was Diagnosed With Nontargetable Advanced Non–Small Cell Lung Cancer. What Now?” Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC
Johnson, M. L., Pennell, N. A., & Borghaei, H. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201231 · Cited by 6
Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?
Heigener, D. F., & Reck, M. (2019) · Drugs · doi:10.1007/s40265-019-01222-w · Cited by 6
Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report
Gunjur, A., Chong, G., Lim, A. Y. L., Lau, E. W. F., Mitchell, P. L. R., John, T., & Arulananda, S. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.014 · Cited by 6
Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma
Luo, J.-W., Guo, Y.-H., Wu, F., Li, X., Sun, X.-C., Wang, J.-L., & Zhou, C. (2021) · Disease Markers · doi:10.1155/2021/3776854 · Cited by 6
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
Rodríguez‐Abreu, D., Cobo, M., García-Román, S., Viteri, S., Jordana‐Ariza, N., García‐Peláez, B., Reguart, N., Aguilar, A., Codony‐Servat, J., Drozdowskyj, A., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.014 · Cited by 6
PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study
Huang, Z., Zhou, C., Xiong, Y., Yang, F., Zeng, F., Jiang, W., Zhang, Y., Yang, H., Liu, L., Zeng, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.909721 · Cited by 6
Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab
Nindra, U., Shahnam, A., Stevens, S. X., Pal, A., Nagrial, A. M., Lee, J., Yip, P. Y., Adam, T., Boyer, M. J., Kao, S. C.-H., et al. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13940 · Cited by 6
The Immune Profile of EGFR -Mutated Non-Small-Cell Lung Cancer at Disease Onset and Progression after Tyrosine Kinase Inhibitors Therapy
Fumagalli, C., Guerini‐Rocco, E., Vacirca, D., Passaro, A., de Marinis, F., & Barberis, M. C. P. (2018) · Immunotherapy · doi:10.2217/imt-2018-0027 · Cited by 6
Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma
Kim, H. K., Joung, J., Choi, Y., Lee, S., Park, B. J., Choi, Y. S., Ryu, D., Nam, J., Lee, M.-S., Park, W., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101386 · Cited by 6
EGFR-Mutant Lung Adenocarcinoma Cell-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression
Zhao, C., Cheng, L., Li, A., Wang, H., Li, X., & Xu, J. (2025) · Biomedicines · doi:10.3390/biomedicines13020482 · Cited by 5
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Balasubramanian, A., Marceaux, C., Kanwal, S., Tarasova, I., Batey, D., Senko, C., Asadi, K., Yokote, K., Palmer, J., Christie, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1449 · Cited by 5
Potential roles of tumor microenvironment in gefitinib-resistant non-small cell lung cancer: A narrative review
Mu-tong, C. H. E. N., Li, B., Zhang, E.-P., & Zheng, Q. L. (2023) · Medicine · doi:10.1097/md.0000000000035086 · Cited by 6
Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice
Araujo, L. H., Ferreira, C. G., Baldotto, C. S. D. R., Mathias, C., de Castro, G., & Coudry, R. A. (2020) · Future Oncology · doi:10.2217/fon-2020-0583 · Cited by 5
Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer
Zhu, L., Ye, D., Lei, T., Wu, J., Wang, W., & Xu, B. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.9 · Cited by 5
Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review
Watanabe, N., Horio, Y., & Fujiwara, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-56 · Cited by 6
Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
Chen, X., Zha, W., Su, M., Meng, N., Cao, S., Niu, B., & Qi, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1053805 · Cited by 5
Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study
Huang, Z., Yan, H., Zeng, L., Xu, Q., Guo, W., Lin, S., Jiang, W., Wang, Z., Li, D., Qin, H., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00614 · Cited by 5
Real-world study of PD-1/L1 immune checkpoint inhibitors for advanced non-small cell lung cancer after resistance to EGFR-TKIs
Wei, K., Zhou, C., Chen, Y., Feng, X., & Tang, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1217872 · Cited by 5
Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
Sathiyapalan, A., Baloush, Z., & Ellis, P. M. (2023) · Current Oncology · doi:10.3390/curroncol30110689 · Cited by 6
Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma
Slomka, J., Berthou, H., Mansuet‐Lupo, A., Blons, H., Fabre, E., Lerner, I., Rance, B., Alifano, M., Chapron, J., Birsen, G., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307161 · Cited by 5
Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations
Pacheco, J. M., & Camidge, D. R. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30112-2 · Cited by 5
Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?
Pourmir, I., Gazeau, B., Basile, H. D. S., & Fabre, E. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.14 · Cited by 5
Application of targeted genome sequencing to brain metastasis from non-small cell lung carcinoma: Case report
Leclair, N. K., Calafiore, R., Wu, Q., Wolansky, L. J., & Bulsara, K. R. (2020) · Neurochirurgie · doi:10.1016/j.neuchi.2020.09.010 · Cited by 5
A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report
Huang, X., Yang, Y., Wang, P., Han‐Zhang, H., & Ding, L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1307 · Cited by 5
Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis
Hu, R., Zhao, Z., Shi, Y., Shi, M., Xia, G., Yu, S., & Feng, J. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3520 · Cited by 5
Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors
Zhou, F., & Zhou, C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.011 · Cited by 5
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature
Baglivo, S., Mandarano, M., Bellezza, G., Minotti, V., Bonaiti, A., Fischer, M. J., Birocchi, I., Roila, F., Metelli, N., Ludovini, V., et al. (2022) · Oncology and Therapy · doi:10.1007/s40487-022-00183-7 · Cited by 5
Atezolizumab in non-small cell lung cancer: the era of precision immuno-oncology
Chow, J. C. H., Cheung, K. M., & Cho, W. C. S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.89 · Cited by 5
EGFR mutation positive non-small cell lung cancer: can we identify predictors of benefit from immune checkpoint inhibitors
Wang, Y., & Ellis, P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.14 · Cited by 5
The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC
Lisberg, A. E., & Garon, E. B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.003 · Cited by 5
Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation
Morgensztern, D., & Govindan, R. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.034 · Cited by 5
Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits
Teng, F., Ju, X., Gao, Z., Xu, J., Li, Y., Wang, Y., Zou, B., & Yu, J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189194 · Cited by 4
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis
Zhu, L., He, W., Xie, C., Yang, S., Zhang, C., & Zhu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512468 · Cited by 4
Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation
Barthélémy, D., Vigneron, A. M., Rousset, X., Guitton, J., Grolleau, E., Raffin, M., Balandier, J., Lescuyer, G., Bardou, M., Geiguer, F., et al. (2025) · FEBS Open Bio · doi:10.1002/2211-5463.13970 · Cited by 6
BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
Fan, F., Zhou, M., Ye, X., Mo, Z., Ma, Y., Luo, L., Liang, X., Liu, H., Weng, Y., Lin, M., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100961 · Cited by 4
Clinicopathological characteristics and prognosis of pulmonary spindle cell carcinoma (PSCC): a population-based retrospective study
Zhang, J., Yan, Y., Hui, B., Bai, S., Ma, W., & Ren, J. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-1841 · Cited by 4
Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review
Hodges, A. W., Sun, K., Sheu, T. G., & Bernicker, E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1193503 · Cited by 4
PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer
Guo, J., Yuan, H., Zhu, Y., Che, Z., Zhang, B., Zhang, D., Zhou, Y. Y., & Xiong, L. (2024) · Medicine · doi:10.1097/md.0000000000036770 · Cited by 4
Utility of molecular markers in predicting local control specific to lung cancer spine metastases treated with stereotactic body radiotherapy
Shor, D., Louie, A. V., Zeng, K. L., Menjak, I. B., Atenafu, E. G., Tseng, C., Detsky, J. S., Larouche, J., Zhang, B., Soliman, H., et al. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04603-8 · Cited by 4

Authors: Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H.
Affiliations: The University of Sydney (AU)
St George Hospital (AU)
Chinese University of Hong Kong (HK)
National Taiwan University (TW)
Corresponding author: Lee, Chee Khoon
ORCID: Lee, Chee Khoon
Man, Johnathan
Links, Matthew
Gebski, Val
Mok, Tony
Yang, James Chih-Hsin
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2017-02
Volume: 12
Issue: 2
Pages: 403-407
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2016.10.007
OpenAlex: W2538232731
Cited by: 839
References: 15
Citations by year: 2026: 47 · 2025: 61 · 2024: 68 · 2023: 84 · 2022: 93 · 2021: 98 · 2020: 100 · 2019: 100 · 2018: 123 · 2017: 62
FWCI: 85.21
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: immune checkpoint inhibitors, EGFR-mutant non-small cell lung cancer, second-line therapy, nivolumab, pembrolizumab, atezolizumab, docetaxel, overall survival, advanced non-small cell lung cancer
MeSH terms: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms, Mutation, Prognosis, Randomized Controlled Trials as Topic, Cell Cycle Checkpoints, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks